Critical care pharmacy in donor management

Progress in Transplantation

Volumn 14, Issue 2, 2004, Pages 105-113

  Phongsamran, Paula V ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CORTICOSTEROID; INSULIN; THYROXINE; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

BRAIN DEATH; CLINICAL PATHWAY; CLINICAL PROTOCOL; DRUG ADMINISTRATION; FLUID THERAPY; HORMONE SUBSTITUTION; HUMAN; INTENSIVE CARE; LIVING DONOR; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; RESUSCITATION; REVIEW; STATISTICS; TRANSPLANTATION;

ADRENAL CORTEX HORMONES; BRAIN DEATH; CLINICAL PROTOCOLS; CRITICAL CARE; CRITICAL PATHWAYS; DRUG ADMINISTRATION SCHEDULE; FLUID THERAPY; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIVING DONORS; RESUSCITATION; THYROXINE; TISSUE AND ORGAN PROCUREMENT; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 6944255653     PISSN: 15269248     EISSN: None     Source Type: Journal    
DOI: 10.7182/prtr.14.2.cx44767r26575316     Document Type: Article

References (37)

1. Organ Procurement and Transplantation Network. Available at: Http://www.optn.org. Accessed August 1, 2003.
2. Razek T, Olthoff K, Reilly M. Issues in potential organ donor management. Surg Clin N Am. 2000;80:1021-1032. (Pubitemid 30396986)
3. Avlonitis VS, Fisher AJ, Kirby JA, Dark JH. Pulmonary transplantation: The role of brain death in donor lung injury. Transplantation. 2003;75:1928-1933. (Pubitemid 36793270)
4. Pratschke J, Wilhelm MJ, Kusaka M, et al. Brain death and its influence on donor organ quality and outcome after transplantation. Transplantation. 1999;67:343-348. (Pubitemid 29094001)
5. Holmquist M, Chabalewski F, Blount T, Edwards C, McBride V, Pietroski R. A critical pathway: Guiding care for the organ donors. Crit Care Nurse. April 1999;19:84-98.
6. Power BM, Van Heerden PV. The physiological changes associated with brain death - current concepts and implications for treatment of the brain dead organ donor. Anaesth Intens Care. 1995;23:26-36.
7. Lindop MJ. Basic principles of donor management for multiorgan removal. Transplant Proc. 1991;23:2463-2464.
8. Scheinkestel CD, Tuxen DV, Cooper DJ, Butt W. Medical management of the (potential) organ donor. Anaesth Intens Care. 1999;23:51-59.
9. Van Bakel AB. The cardiac transplant donor: Identification, assessment, and management. Am J Med Sci. 1997;314:153-163. (Pubitemid 27381736)
10. Sazontseva IE, Kozlov IA, Moisuc YG, Ermolenko AE, Afonin VV, Ilnitskiy VV. Hormonal response to brain death. Transplant Proc. 1991;23:2467.
11. Pennefather SH, Bullock RE, Mantle D, Dark JH. Use of low dose arginine vasopressin to support brain-dead organ donors. Transplantation. 1995;59:58-62.
12. Katz K, Lawler J, Wax J, O'Connor R, Nadkarni V. Vasopressin pressor effects in critically ill children during evaluation for brain death and organ recovery. Resuscitation. 2000;47:33-40.
13. Micromedex Healthcare Series. Available at: Http://www healthcare.micromedex.com. Accessed July 14, 2003.
14. Guesde R, Barrou B, Leblanc I, et al. Administration of desmopressin in brain-dead donors and renal function in kidney recipients. Lancet. 1998;352:1178-1181. (Pubitemid 28458532)
15. Debelak L, Pollak R, Reckard C. Arginine vasopressin versus desmopressin for the treatment of diabetes insipidus in the brain dead organ donor. Transplant Proc. 1990;22:351-352. (Pubitemid 20160379)
16. Salim A, Vassiliu P, Velmahos GC, et al. The role of thyroid hormone administration in potential organ donors. Arch Surg. 2001;136:1377-1380. (Pubitemid 33117043)
17. Mariot J, Sadoune LO, Jacob F, et al. Hormone levels, hemodynamics, and metabolism in brain dead organ donors. Transplant Proc. 1995;27:793-794.
18. Garcia-Fages LC, Cabrer C, Valero R, Manyalich M. Hemodynamic and metabolic effects of substitutive triiodothyronine therapy in organ donors. Transplant Proc. 1993;25:3038-3039. (Pubitemid 24007214)
19. Gramm HJ, Meinhold H, Bickel U, et al. Acute endocrine failure after brain death. Transplantation. 1992;54:851-857.
20. Randell TT, Hockerstedt KAV. Triiodothyronine treatment is not indicated in brain-dead multiorgan donors: A controlled study. Transplant Proc. 1993;25:1552-1553. (Pubitemid 23079097)
21. Novitsky D, Cooper DKC, Reichart B. Hemodynamic and metabolic responses to hormonal therapy in brain-dead potential organ donors. Transplantation. 1987;43:852-854. (Pubitemid 17084263)
22. Novitsky D, Cooper DKC, Chaffin JS, Greer AE, DeBault LE, Zuhdi N. Improved cardiac allograft function following triiodothyronine therapy to both donor and recipient. Transplantation. 1990;49:311-316. (Pubitemid 20088167)
23. Novitsky D. Triiodothyronine replacement, the euthyroid sick syndrome, and organ transplantation. Transplant Proc. 1991;23:2460-2462.
24. Jeevanandam V. Triiodothyronine: Spectrum of use in heart transplantation. Thyroid. 1997;7:139-145. (Pubitemid 27132908)
25. Reasner CA, Talbert RL. Pharmacotherapy: A Pathophysiologic Approach. 4th ed. Stamford, Conn: Appleton & Lange; 1999:1258-1260.
26. Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation. 2003;75:482-487. (Pubitemid 36241143)
27. Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus conference report - maximizing use of organs recovered from the cadaver donor: Cardiac recommendations. Circulation. 2002;106:836-841.
28. Follette DM, Rudich SM, Babcock WD. Improved oxygenation and increased lung donor recovery with high-dose steroid administration after brain death. J Heart Lung Transplant. 1998;17:423-429. (Pubitemid 28196962)
29. Masson F, Thicoipe M, Gin H, et al. The endocrine pancreas in brain-dead donors. Transplantation. 1993;56:363-367.
30. Wheeldon DR, Biol MI, Potter CDO, et al. Transforming the "unacceptable" donor: Outcomes from the adoption of a standardized donor management technique. J Heart Lung Transplant. 1995;14:734-742.
31. Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation. 2003;75:1336-1341. (Pubitemid 36513044)
32. Critical Pathway for the Organ Donor. Available at: Http://www unos.org/resources. Accessed March 25, 2004.
33. Jassem W, Koo DDH, Muiesan P, et al. Non-heart-beating versus cadaveric and living-donor livers: Differences in inflammatory markers before transplantation. Transplantation. 2003;75:1386-1390. (Pubitemid 36513053)
34. Hauptman PJ, O'Connor KJ. Medical progress: Procurement and allocation of solid organs for transplantation. N Engl J Med. 1997;336:422-431. (Pubitemid 27081907)
35. Abt P, Crawford M, Desai N, Markmann J, Olthoff K, Shaked A. Can controlled non-heart-beating donors provide a solution to the organ shortage? Transplantation. 2003;75:1627-1628.
36. Abt P, Crawford M, Desai N, Markmann J, Olthoff K, Shaked. A. Liver transplantation from controlled non-heartbeating donors: An increased incidence of biliary complications. Transplantation. 2003;75:1659-1663. (Pubitemid 36629146)
37. Fukumori T, Kato T, Levi D, et al. Use of older controlled non-heart-beating donors for liver transplantation. Transplantation. 2003;75:1171-1174. (Pubitemid 36513016)